

23 January 2018 EMA/895561/2018 Veterinary Medicines Division

Monthly report on application procedures, guidelines and related documents for veterinary medicines

December 2018

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific advice requests;
- applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification and re-classifications of products as Minor Use Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.




An agency of the European Union

© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.


Statistics on pre- and post-authorisation applications for medicinal products for veterinary use

Scientific advice requests				
	2015	2016	2017	2018
Submitted and validated	27	18	17	25
Advice given	29	18	20	23



Scientific advice requests submitted and advice given

Initial evaluation of marketing authorisation applications Full (submitted) Abridged/generics (submitted) Withdrawals Positive opinions Negative opinions



MMA submissions and outcomes


Monthly report on application procedures, guidelines and related documents for veterinary medicines EMA/895561/2018

Marketing authorisations				
	2015	2016	2017	2018
Granted	17	7	18	9
Withdrawals	3	1	0	5
Refusal	1	0	0	1
Not renewed	0	1	0	2

Extensions — applications

	2015	2016	2017	2018
Submitted	3	3	5	1
Withdrawals	0	0	0	0
Positive opinions	6	5	2	5
Negative opinions	1	0	0	0

Variations — applications submitted				
	2015	2016	2017	2018
Type-IA variations	196	243	238	330
Type-IB variations	116	126	130	147
Type-II variations	61	41	78	112
Transfers	5	5	3	17



Post-authorisation: submissions of variations and transfers

Renewals — applications Submitted Positive opinions Negative opinions

Monthly report on application procedures, guidelines and related documents for veterinary medicines EMA/895561/2018

Establishment of MRLs for new substances ¹ — applications					
2015 2016 2017 201					
Submitted	4	6	3	3	
Withdrawals	1	0	2	2	
Positive opinions ^{2,3}	3 (1)	2	4	1	
Negative opinions	0	0	0	0	


Extensions/modifications of MRLs⁴ – applications

	2015	2016	2017	2018
Submitted	3	1	3	1
Withdrawals	0	1	0	0
Positive opinions ²	2	3	2	2
Negative opinions	0	0	0	0

Review of opinions/extrapolations of MRLs ⁵				
	2015	2016	2017	2018
Submitted	1	0	0	1
Opinion ²	3	0	0	1

Substances considered as not falling within the scope of Regulation (EC) No 470/2009 requests

	2015	2016	2017	2018
Submitted	14	4	4	2
Agreed	18	3	2	1
Not agreed	2	0	0	0
Scientific advice recommended	1	1	1	2



MRL-related submissions

¹ Establishment of MRLs for new substances under article 3 of Regulation (EC) No 470/2009.


² Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances previously with provisional MRLs.

³ Re-examinations of opinions are indicated in brackets.
 ⁴ Extension or modification of MRLs under article 3 of Regulation (EC) No 470/2009.

⁵ Review of opinions under article 11 of Regulation (EC) No 470/2009 or requests under article 27 of Regulation (EC) No 470/2009.

MUMS/limited market (re)classification requests — outcome					
	2015	2016	2017	2018	
MUMS/limited market with financial incentives	7	1	3	1	
MUMS/limited market without financial incentives	17	17	15	15	
MUMS/limited market reclassification with financial incentives ⁶	1	1	2	0	
MUMS/limited market reclassification without financial incentives ⁶	0	3	7	5	
Not MUMS/limited market	5	3	2	7	


Outcome of MUMS/limited market (re-)classification



Arbitrations and referrals

	2015	2016	2017	2018	
Arbitrations and referrals submitted	7	8	1	5	
Opinions ⁷	5	7	7(1)	3(1)	

Arbitrations and referrals submissions and opinions



⁶ For re-classification the first year available is 2014.

⁷ Re-examinations of opinions are in brackets.

CVMP opinions in 2018 on medicinal products for veterinary use

Positive opinions

Product Invented name 	Marketing authorisation holder	Target species	Regulatory information Procedure number
INN/Common name			Opinion date
Clevorropinirole	Orion Corporation	Dogs	EMEA/V/C/004417/000015/02/2018
Bravecto Plusfluralaner/moxidectin	Intervet International B.V.	Cats	EMEA/V/C/004440/000015/03/2018
Dany's BienenWohloxalic acid dihydrate	 Dany's BienenWohl GmbH 	Honey bees	EMEA/V/C/004667/000019/04/2018
 Ubac Streptococcus uberis vaccine (inactivated) 	 Laboratorios Hipra, S.A. 	Cattle	 EMEA/V/C/004595/0000 22/05/2018
 Arti-Cell Forte chondrogenic induced equine allogeneic peripheral blood- derived mesenchymal stem cells 	Global Stem cell Technology NV	Horses	 EMEA/V/C/004727/0000 21/06/2018
Cortacarehydrocortisone aceponate	Ecuphar NV	• Dogs	EMEA/V/C/004689/000021/06/2018
IsemidTORASEMIDE	CEVA Santé Animale	• Dogs	EMEA/V/C/004345/000008/11/2018
 Syvazul BTV Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 3) 	 LABORATORIOS SYVA, S.A.U 	• Sheep, Cattle	EMEA/V/C/004611/000008/11/2018
EVANTCoccidiosis vaccine live for chickens	• LABORATORIOS HIPRA, S.A.	Chickens	EMEA/V/C/004902/00006/12/2018
KriptazenHALOFUGINONE	• Virbac S.A.	Newborn calves	EMEA/V/C/004868/000006/12/2018

Negative opinions

Product Invented name INN/Common name 	Applicant	Target species	Regulatory information Procedure number Opinion date
 Horse Allo Allogeneic equine adipose-derived mesenchymal stem cells 	Centauri Biotech SL	Horses	 EMEA/V/C/004328/0000 21/06/2018
 HorStem Equine umbilical cord mesenchymal stem cells 	EquiCord-Ymas S.L.	Horses	EMEA/V/C/004265/000011/10/2018
Longrangeeprinomectin	Merial	Cattle	EMEA/V/C/004291/000011/10/2018

CVMP opinions in 2018 on establishment of MRLs

Positive opinions

ProductSubstance	Target species	Regulatory information Procedure number Opinion date
Paromomycin	Poultry eggs	EMEA/V/MRL/003517/EXTN/000315/02/2018
Isoflurane	Porcine	EMEA/V/MRL/003647/EXTN/000215/03/2018
Diflubenzuron	Salmonidae	EMEA/V/MRL/003135/MODF/000315/03/2018
Ovotransferrin	Chicken and poultry	EMEA/V/MRL/004856/FULL/000119/07/2018

Arbitrations and referrals in 2018

Ongoing procedures

Type of procedure	Date Clock start CVMP opinion 	Product Product name INN
 Referral under Article 34 of Directive 2001/82/EC (re-examination) 	 13/07/2016 05/10/2017 15/02/2018 	 Girolan and its associated name Apralan Apramycin sulfate
 Referral under Article 13 of Regulation (EC) No. 1234/2008 	06/09/201715/02/2018	 Seresto and its associated name Foresto Imidacloprid and flumethrin
Referral under Article 35 of Directive 2001/82/EC	• 14/02/2018	 Veterinary medicinal products containing 50 mg closantel per ml presented as solutions for injection for subcutaneous use in sheep Closantel
 Procedure under Article 30(3) of Regulation (EC) No. 726/2004 	14/03/201819/07/2018	 Veterinary medicinal products for food producing species containing diethanolamine as an excipient Diethanolamine (excipient)
 Procedure under Article 30(3) of Regulation (EC) No. 726/2004 	18/04/201808/11/2018	 Veterinary medicinal products containing gentamicin for parenteral administration to horses Gentamicin
 Referral under Article 35 of Directive 2001/82/EC 	• 10/10/2018	 Veterinary medicinal products containing paromomycin to be administered parenterally to pigs Paromomycin
 Referral under Article 35 of Directive 2001/82/EC 	• 10/10/2018	 Veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep Tylosin

Guidelines and working documents in 2018

CVMP quality

Reference number	Document title	Status
EMA/CVMP/QWP/798401/2015	Guideline on Manufacture of the veterinary finished dosage form	Adopted for consultation February 2018 (End of consultation 31 August 2019)
EMA/CHMP/CVMP/QWP/496873/ 2018	Guideline on the quality of water for pharmaceutical use	Adopted for consultation July 2018 (End of consultation 15 May 2019)
EMA/CVMP/QWP/153641/2018	Reflection paper on risk management requirements for elemental impurities in veterinary medicinal products	Adopted for consultation November 2018 (End of consultation 31 August 2019)
EMEA/CVMP/134/02 Rev 4	Guideline on Active Substance Master File Procedure	Adopted November 2018
EMA/CHMP/CVMP/QWP/850374/ 2015	Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container	Adopted December 2018

CVMP safety

Reference number	Document title	Status
EMA/CVMP/SWP/779037/2017	Concept paper for the revision of the guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market	Adopted for consultation January 2018 (End of consultation 28 February 2018)
EMA/CVMP/SWP/721059/2014	Guideline on user safety of topically administered veterinary medicinal products	Adopted April 2018
EMA/CHMP/CVMP/SWP/246844/ 2018	Questions and answers on implementation of risk-based prevention of cross-contamination in production and 'Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities'	Adopted April 2018

Reference number	Document title	Status
EMA/CVMP/ERA/103555/2015	Guideline on assessing the environmental and human health risks of veterinary medicinal products in groundwater	Adopted April 2018
EMA/CVMP/SWP/735325/2012	Guideline on determination of withdrawal periods for edible tissues	Adopted September 2018
EMA/CVMP/SWP/66781/2005-	Revised guideline on safety and	Adopted for consultation
<u>Rev.2</u>	residue data requirements for veterinary medicinal products	December 2018
	intended for minor use or minor	(End of consultation 31
	species (MUMS)/limited market	August 2019)
EMA/CVMP/SWP/377245/2016	Guideline on assessment and	Adopted December 2018
	control of DNA reactive (mutagenic)	
	impurities in veterinary medicinal	
	products	

CVMP efficacy

Reference number	Document title	Status
EMA/CVMP/383441/2005-Rev.1	Guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances	Adopted for consultation April 2018 (End of consultation 30 September 2018)
EMA/CVMP/EWP/278031/2015	Guideline on data requirements for veterinary medicinal products for the prevention of transmission of vector- borne diseases in dogs and cats	Adopted for consultation July 2018 (End of consultation 31 August 2019)
EMA/CVMP/EWP/310225/2014	Reflection paper on resistance in ectoparasites	Adopted for consultation September 2018 (End of consultation 31 August 2019)
EMA/CVMP/016/2000-Rev.3	Guideline on the conduct of bioequivalence studies for veterinary medicinal products	Adopted December 2018
EMA/CVMP/EWP/755916/2016	Guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances	Adopted for consultation December 2018 (End of consultation 31 August 2019)
EMA/CVMP/EWP/77872/2018	Questions and answers on the CVMP guideline on the "Guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees"	Adopted December 2019

CVMP pharmacovigilance

Reference number	Document title	Status
EMA/CVMP/PhVWP/171122/2016	Revised recommendation for the basic surveillance of EudraVigilance Veterinary (EVVet) data for centrally authorised products (CAPs)	Adopted May 2018
EMA/CVMP/PhVWP/10418/2009- Rev10	Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products	Adopted June 2018
EMA/CVMP/PhVWP/288284/2007 -Rev.11	Guidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans	Adopted June 2018
EMA/CVMP/PhVWP/145186/2013	Q&A on adverse event reporting	Adopted June 2018
EMA/CVMP/PhVWP/126661/2009	Q&A on preparation, management and assessment of periodic safety update reports (PSURs)	Adopted June 2018

CVMP antimicrobials

Reference number	Document title	Status
EMA/CVMP/383441/2005-Rev.1	Guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances	Adopted for consultation April 2018 (End of consultation 30 September 2018)
EMA/CVMP/AWP/721118/2014	Reflection paper on use of aminoglycosides in animals in the European Union: development of resistance and impact on human and animal health	Adopted June 2018
EMA/CVMP/AWP/706442/2013	Guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals	Adopted for consultation July 2018 (End of consultation 31 October 2018)
EMA/CVMP/849775/2017	Reflection paper on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation	Adopted for consultation July 2018 (End of consultation 31 January 2019)

Reference number	Document title	Status
EMA/CVMP/AWP/842786/2015	Reflection paper on the use of aminopenicillins and their beta- lactamase inhibitor combinations in animals in the European Union: development of resistance and	Adopted for consultation September 2018 (End of consultation 21 December 2019)
EMA/CVMP/AWP/237294/2017	impact on human and animal health Reflection paper on off-label use of antimicrobials in veterinary medicine in the European Union	Adopted November 2018

CVMP immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/315887/2017	Guideline on the use of adjuvanted veterinary vaccines	Adopted for consultation June 2018 (End of consultation 15 January 2019)
<u>EMA/CVMP/IWP/105506/2007-</u> <u>Rev.1</u>	Revised guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and- Mouth disease (FMD)	Adopted December 2018
EMA/CVMP/IWP/170689/2016	Guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats	Adopted for consultation December 2018 (End of consultation 31 August 2019)

CVMP environmental risk assessment

Reference number	Document title	Status
<u>EMEA/CVMP/ERA/172074/2008</u> <u>Rev. 6</u>	Questions and Answers on the implementation of the CVMP guideline on environmental impact assessment for veterinary medicinal products in support of the VICH GL6 (Phase I) and GL38 (Phase II)	Adopted January 2018
EMA/CVMP/ERA/103555/2015	Guideline on assessing the environmental and human health risks of veterinary medicinal products in groundwater	Adopted April 2018
EMA/CVMP/ERA/632109/2014	Reflection paper on antimicrobial resistance in the environment: considerations for current and future risk assessment of veterinary medicinal products	Adopted for consultation November 2018 (End of consultation 31 August 2019)

CVMP novel therapies

No guidelines or working documents have yet been agreed in 2018.

Replacement, Reduction, Refinement of animal testing (3Rs)

Reference number	Document title	Status
EMA/CHMP/CVMP/3Rs/677407/2	Review and update of EMA guidelines	Adopted June 2018
<u>015</u>	to implement best practice with	
	regard to 3Rs (replacement,	
	reduction and refinement) in	
	regulatory testing of medicinal	
	products – report on actions taken	
EMA/CHMP/CVMP/3Rs/164002/2	Reflection paper providing an	Adopted June 2018
<u>016</u>	overview of the current regulatory	
	testing requirements for veterinary	
	medicinal products and opportunities	
	for implementation of the 3Rs	

General

Reference number	Document title	Status
EMA/CVMP/VICH/517152/2013	VICH GL57: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic	Adopted for consultation January 2018 (end of consultation 15 June 2018)
EMA/CVMP/VICH/335918/2016	species VICH GL58 Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV	Adopted for consultation July 2018 (end of consultation 31 December 2018)
EMA/CVMP/VICH/176637/2014	VICH GL56 on Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food- producing species: study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods	Adopted July 2018